Physician profile
Jay J Singh
NPI 1154313211
$101,715.34
in general payments reported to CMS, 2019-2025
31 companies · $7,721 in 2025
The $7,721 reported for 2025 was more than what 92% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $24K · 2021: $17K · 2022: $3,002 · 2023: $8,995 · 2024: $2,567 · 2025: $7,721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,970 · Education: $6,500 · Travel and Lodging: $3,312 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,970.45 |
| Education | $6,500.00 |
| Travel and Lodging | $3,311.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $95,693.37 | 2019-2025 | |
| Applied Medical Resources Corporation | $1,761.25 | 2019-2025 | |
| Medical Device Business Services, INC. | $1,068.15 | 2025 | Echelon Circular |
| Medtronic, INC. | $811.16 | 2021-2025 | Signia, Manoscan, V-Loc 180 |
| Ethicon US, LLC | $516.26 | 2019-2025 | Echelon Circular, Enseal X1, Stratafix |
| Ambu INC. | $297.49 | 2021-2024 | |
| Edwards Lifesciences Corporation | $209.62 | 2024 | Hemosphere |
| Thd America, INC. | $172.97 | 2024 | |
| Integra Lifesciences Corporation | $168.65 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Baxter Healthcare | $160.51 | 2019-2025 | Perclot, Floseal, Seprafilm |
| Dilon Technologies, INC. | $144.58 | 2025 | Hemoblast Bellows |
| Depuy Synthes Sales INC. | $118.76 | 2023 | Matrixrib |
| Axonics, INC. | $89.79 | 2020-2022 | |
| Vertex Pharmaceuticals Incorporated | $57.46 | 2025 | |
| Ferring Pharmaceuticals INC. | $50.35 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $41.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.27 | 2019-2020 | |
| Tei Biosciences INC | $39.09 | 2019 | |
| Covidien Lp | $35.18 | 2019 | |
| Mallinckrodt Hospital Products INC. | $35.00 | 2022 | |
| Palette Life Sciences, INC. | $29.49 | 2022 | |
| Merck Sharp & Dohme LLC | $26.49 | 2019-2020 | |
| Innovation Technologies INC | $23.14 | 2025 | Irrisept |
| Shire North American Group INC | $22.23 | 2019 | |
| Boston Scientific Corporation | $22.21 | 2025 | Axonics |
| Davol INC. | $21.52 | 2019 | |
| Tela Bio, INC. | $17.63 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $15.79 | 2023 | Uptravi, Opsumit |
| Hollister Incorporated | $12.93 | 2022 | |
| Hydrofera LLC | $12.92 | 2023 | Hydrofera Blue |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$142,560.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.